Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies  by Boeckh, Michael et al.
Biol Blood Marrow Transplant 21 (2015) 24e29Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgRecent Advances in Cytomegalovirus: An Update
on Pharmacologic and Cellular TherapiesMichael Boeckh 1, William J. Murphy 2, Karl S. Peggs 3,*
1Division of Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
2Division of Hematology/Oncology, Departments of Dermatology and Internal Medicine, University of California, Davis School of Medicine, Davis, California
3Department of Haematology, University College London Cancer Institute, London, United KingdomArticle history:
Received 22 October 2014
Accepted 3 November 2014
Key Words:
Cytomegalovirus
Antiviral drugs
Cellular therapy
Natural killer cellsFinancial disclosure: See Acknowl
* Correspondence and reprint
Institute, 72 Huntley Street, Londo
E-mail address: k.peggs@cance
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
The 2015 Tandem American Society for Blood and Marrow Transplantation/Center for International Blood and
Marrow Transplant Meetings provide an opportunity to review the current status and future perspectives on
therapy for cytomegalovirus (CMV) infection in the setting of hematopoietic stem cell transplantation (HSCT).
After many years during which we have seen few tangible advances in terms of new antiviral drugs, we are
now experiencing an exciting period of late-stage drug development, characterized by a series of phase III
trials incorporating a variety of novel agents. These trials have the potential to shift our current standard
therapeutic strategies, which generally involve pre-emptive therapy based on sensitive molecular surveil-
lance, towards the prophylactic approaches we see more generally with other herpes viruses such as herpes
simplex and varicella zoster. This comes at a time when the promise of extensive preclinical research has been
translated into encouraging clinical responses with several cellular immunotherapy strategies, which have
also been moved towards deﬁnitive late-stage clinical trials. How these approaches will be integrated with
the new wave of antiviral drugs remains open to conjecture. Although most of the focus of these cellular
immunotherapy studies has been on adaptive immunity, and in particular T cells, an increasing awareness of
the possible role of other cellular subsets in controlling CMV infection has developed. In particular, the role of
natural killer (NK) cells is being revisited, along with that of gd T cells. Depletion of NK cells in mice results in
higher titers of murine CMV in tissues and increased mortality, whereas NK cell deﬁciency in humans has
been linked to severe CMV disease. We will review recent progress in these areas.
 2015 American Society for Blood and Marrow Transplantation.ADVANCES IN PHARMACOLOGIC THERAPIES
Current Approaches
Over the past 2 decades, both prophylaxis and preemptive
therapy have been used to prevent CMV disease in the HSCT
setting [1]. Although preemptive therapy is most commonly
used, prophylaxis is favored by some centers for high-risk
patients, such as recipients of unrelated, HLA-mismatched
or cord blood products. Although both strategies are effec-
tive for prevention of CMV, they rely on available drugs with
signiﬁcant toxicities, including marrow toxicity for ganci-
clovir, valganciclovir, and cidofovir, and renal toxicity for
foscarnet and cidofovir [2,3].
The treatment of CMV disease after HSCT typically con-
sists of ganciclovir at induction doses for 2 to 3 weeks,edgments on page 28.
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ty for Blood and Marrow Transplantation.followed by maintenance dosing until all signs and symp-
toms are undetectable. When cytopenias are present, fos-
carnet is used as alternative. Valganciclovir is sometimes
used after an initial response is documented, provided that
there is good oral intake and adherence to the regimen;
however, no systematic evaluations of this approach exists.
Although CMV gastrointestinal disease can be treated with
an antiviral drug alone, recommendations for CMV pneu-
monia include the addition of intravenous immunoglobulin
[2,4]. Drug-resistant CMV disease is rare after HSCT but
should be suspected in patients with poor clinical or virologic
responses and pre-exposure to the antiviral drug used. Pa-
tients who are on antiviral drugs andwho have had viral load
increases for more than 2 weeks may have resistance. If drug
resistance is suspected, genotypic testing and switching to an
alternative drug is recommended as ﬁrst-line approach [2,5].
Viral load can be used to monitor the response to treatment.
In patients with documented drug resistance or those who
are critically ill, often few options exist and none are
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below may be available for use in some situations.
Future Approaches
Because of the safety proﬁle of currently available drugs,
efforts have been made in developing new compounds with
similar or improved efﬁcacy and improved toxicity. Also,
several presently available drugs have been reported to have
anti-CMV activity in vitro. The following summarizes new
antiviral agents being evaluated in clinical trials in HSCT
recipients.
Maribavir, a UL97 protein kinase inhibitor, is an oral drug
with speciﬁc activity against CMV [6]. A phase II dose-
ranging study in HSCT recipients showed that CMV infec-
tion or disease was reduced at all 3 dose levels tested, but a
subsequent phase III study that used the lowest dose (100mg
twice daily) failed to prevent CMV disease [7]. The failure of
the study was primarily attributed to the dose used in that
study [8]. Maribavir has in vitro activity against ganciclovir-
or cidofovir-resistant CMV, and small case series suggest a
possible clinical beneﬁt at higher doses [9]. Therefore, 2
ongoing phase II dose-ranging trials are examining higher
doses of maribavir treatment of refractory or resistant CMV
disease (clinicaltrials.gov NCT01611974) and as preemptive
therapy (EudraCT: 2010-024247-32).
Letermovir (AIC-246), a CMV terminase inhibitor, is
another highly selective anti-CMV agent [10,11]. The drug
can be given orally or intravenously and is highly active
against wild-type and drug-resistant CMV in vitro. In vivo
experience for multidrug-resistant CMV disease is limited
[12]. A phase II dose-escalation study in CMV-seropositive
HLA-matched HSCT recipients showed a reduction of pro-
phylaxis failure (deﬁned as drug discontinuation due to CMV
infection or disease or any cause) in patients receiving the
240mg of letermovir compared with those receiving placebo
[13]. The drug was tolerated well, with similar adverse event
rates in letermovir and placebo recipients. A phase III ran-
domized multicenter trial is currently ongoing using a
similar trial design as the phase II trial (clinicaltrials.gov
NCT02137772).
Brincidofovir (CMX-001) is a new broad spectrum anti-
viral agent that has in vitro activity against herpesviruses,
polyomaviruses, adenoviruses, papillomaviruses, and variola
virus [6]. It is a lipid-conjugated nucleotide analogue of
cidofovir that has a high oral bioavailability and long half-life,
allowing twice weekly oral dosing. In contrast to its parent
compound, brincidofovir is not a substrate for the human
organic anion transporters and, therefore, has signiﬁcantly
reduced potential to cause renal toxicity. A phase II dose-
escalation study in HSCT recipients showed a reduction of
CMV infection or disease in patients receiving brincidofovir
at doses of 200 mg per week for prophylaxis started at
engraftment [14]. The most common side effect was diarrhea
in patients receiving CMX001 at doses of 200 mg weekly or
higher. It was dose limiting at 200 mg twice weekly. There
was no difference in renal or hematologic adverse effects
between brincidofovir and placebo recipients. A phase III
randomized multicenter trial of brincidofovir at a dose of
100 mg twice weekly is currently ongoing using a similar
trial design as the phase II trial (clinicaltrials.gov
NCT01769170).
Leﬂunomide is a Food and Drug Admin-
istrationeapproved drug for the treatment of arthritis with
documented activity against several viruses, including CMV
and BK virus [15]. Leﬂunomide has been used in salvagesituations for CMV disease with mixed results [16]; however,
no systematic evaluation of the efﬁcacy and toxicity of
leﬂunomide either as mono- or combination therapy has
been performed.
Finally, artesunate is an antimalarial agent that also has
broad antiviral activity in vitro against herpes viruses [17],
hepatitis viruses, and human immunodeﬁciency virus
because of its ability to downregulate NF-kB or Sp1 pathways
[18]. There are anecdotal reports of its effectiveness in
patients with complicated CMV infection, including
multidrug-resistant CMV [19]; however, no systematic
evaluation of the efﬁcacy and toxicity of artesunate for CMV
treatment has been performed.
Future Perspectives
Preemptive antiviral therapy substantially reduced the
incidence of CMV disease after HSCT in the past 20 years.
Several new drugs are now in advanced stage of clinical
evaluation and may be available for more effective and less
toxic prevention of CMV in HSCT recipients. Studies are also
needed to determine whether these drugs can be used in
combination to reduce mortality of CMV pneumonia.
ADVANCES IN T CELL THERAPIES
Because the primary risk factor for CMV infection after
HSCT is considered to be a deﬁcit in number and function
of CMV-reactive T cells [20], a number of investigators
have addressed the possibility that adoptive transfer of
donor-derived (and, in some cases, third-party) CMV-reac-
tive T cells will hasten reconstitution of protective patho-
genespeciﬁc immunity, potentially reducing the infective
burden and associated treatment costs [21]. Derivation of a
therapeutic cellular product is technically easiest when the
original stem cell graft donor has pre-existing immunity to
CMV. In these cases, direct selection of virus-speciﬁc T cells,
or expansion of such cells in ex vivo, is usually feasible. Most
of the early demonstrations of proof of concept relied on an
ex vivo expansion step, limiting more widespread clinical
application [22,23]. Subsequent reﬁnements in culture con-
ditions allowed more rapid cell expansion [24-27]. More
recently, increasingly robust strategies for direct selection of
virus-speciﬁc T cells from seropositive donors have been
developed, including selection after restimulation with viral
peptides according to secretion of IFN-gamma or up-
regulation of cell surface activation markers [28,29], or
direct selection of unstimulated cells based on binding of
class I HLA-multimers [30,31]. Each strategy produces a
therapeutic product that differs in terms of cellular compo-
sition, purity, antigen speciﬁcity, and functional character-
istics. Application in subsequent phase I and II studies has
also introduced further variation in terms of the cell doses
employed, and the timing of and indication for intervention
(eg, prophylactic, preemptive, or for clinically “resistant”
infection). Nevertheless, most clinical studies reach a broadly
similar conclusion: immunity can be restored in the absence
of signiﬁcant toxicity and with a low risk of induction of
graft-versus-host disease (GVHD) [32]. Of course, early phase
studies may be inﬂuenced by selection biases, and exclusion
of those with clinically signiﬁcant active GVHD is an obvious
bias of these early studies. Furthermore, there are data to
suggest that immune reconstitution after HSCT is dependent
to some degree on the frequency of CMV-speciﬁc T cells in
the donor graft. Because low precursor frequency correlates
with failure to generate a therapeutic product in some cases,
a further bias is introduced in uncontrolled studies. These
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to be evaluated just like any other drug in prospective ran-
domized conﬁrmatory studies.
The design of conﬁrmatory studies employing cellular
therapeutics, particularly if delivered without the ﬁnancial
support of large pharmaceutical industry partners, has to
take into consideration a number of key factors relating to
incidence of CMV infection and likelihood of generation of a
patient-speciﬁc bespoke product that is not then utilized
because of lack of infection or precluding clinical features,
such as GVHD. For these reasons, we focused on CMV-
seropositive recipients receiving T celledepleted grafts.
This patient group has a very high incidence of CMV infection
and a low baseline incidence of GVHD. The development of
“direct” selection technologies that obviate the need for
ex vivo expansion also aids trial development. Two ran-
domized conﬁrmatory studies have recently been completed
in the United Kingdom; 1 a study of prophylaxis in the sibling
donor setting (IMPACT) and the other of preemptive therapy
in the unrelated donor setting (ASPECT), using CMV-speciﬁc
T cells selected either by HLA-streptamers (IMPACT/ASPECT),
or by gamma-catch technology (IMPACT) according to HLA
type. The control groups received standard viral PCR-based
surveillance, with standardized criteria for intervention and
stoppage of antiviral drugs. Further studies of CMV-speciﬁc T
cell therapies are planned in the T cellereplete setting and in
patients receiving corticosteroids for GVHD. The results will
require integration with changes in practice that evolve with
the availability of new antiviral drug therapies. For example,
it is well known that acyclovir is very effective at preventing
varicella infection/reactivation, but also that a signiﬁcant
fraction of patients will experience symptomatic infection
when prophylaxis is stopped because of a lack of reconsti-
tution of protective immunity while receiving antiviral
therapy [33]. A similar picture has been reported with the
use of prophylactic ganciclovir for CMV, with delays in
reconstitution of protective immunity presumably relating to
lack of exposure to viral replication and DNAemia during
prophylaxis [34]. It is possible that the combination of
adoptive cell therapy and an abbreviated period of prophy-
laxis with a new antiviral drug will prove optimal.
There are limitations associated with some of the new
strategies. The HLA coverage of a given population will vary
widely according to geographical location and local varia-
tions. Thus, therapies targeting populations with speciﬁc
HLA expression patterns will be more or less relevant
according to the nature of local patient and donor pop-
ulations. CMV seropositivity rates are also variable. There are
a number of potential solutions being evaluated for patients
without seropositive donors. A “third-party” bank of virus-
speciﬁc cells offers a number of potential advantages in
terms of models of delivery and opportunities for commer-
cialization. Rapid availability for use directed by a “best
available HLA match” algorithm (wherein the transferred
cells need to recognize the pathogen in the context of a
shared HLA allele) is particularly attractive. Although proof-
of-concept is available [35], similar issues regarding
possible selection bias need to be addressed in larger
conﬁrmatory studies before more widespread adoption.
Potential issues here relate to possible alloreactivity in either
a host-versus-graft direction, resulting in rejection of the
adoptively transferred populations before they can exert the
desired effect, or in the opposite graft-versus-host direction,
resulting in third-party GVHD if the cells engraft robustly.
Whether third-party cells engender more rapidreconstitution of second-party immunity derived from the
original stem cell donor, either by acting as a cellular vaccine
or through a brief burst of lysis of virally infected host cells,
remains unclear. If such strategies were proven to be clini-
cally effective, they would likely be more easily applied on a
widespread basis than the alternative strategy of induction of
primary immune responses ex vivo, with subsequent
expansion and adoptive transfer [36].
Alternative strategies are also being evaluated that may
achieve a broader repertoire of immune reconstitution
against both known and unknown pathogens. These include
transfer of memory T cell populations depleted of the naïve
compartment that contains most of the alloreactive potential
of the graft [37]. Delivery in the absence of GVHDwould offer
signiﬁcant advantages overmore piecemeal reconstitution to
multiple known pathogens.
ADVANCES IN UNDERSTANDING THE BIOLOGICAL ROLE
OF NK CELLS
NK cells were ﬁrst described as a function in the 1960s.
Lethally irradiated and unsensitized mice were capable of
rejecting bone marrow cell allografts. Later, this hemato-
poietic stem cell (HSC) resistance was found to be different
than classical solid tissue allograft rejection in that F1 hybrid
mice were capable of rejecting parental bone marrow cell
allografts, placing this phenomenon at variance with the
classical laws of transplantation mediated by Tcells and solid
tissue allografts [38]. This phenomenon was called hybrid
resistance. It was in 1975 that this in vivo phenomenon could
be tied with the ability of peripheral bloodmononuclear cells
to spontaneously lyse transformed or virally infected cells in
a non-MHC restricted manner [39]. The cell type responsible
for these effects was found to be a large granular lymphocyte
that shared many but not all markers present on T cells. The
deﬁnition of an NK cell arises, therefore, by its function
(usually spontaneous non-MHC restricted lysis of a tumor
cell line, such as K562 in human or YAC-1 in mice) and
phenotype, which is characterized by the presence of some
markers (eg, CD56 in humans, NK1.1 in mice, and CD122 as
well as CD16 in both) and absence of others (eg, CD3 and
TCR). This inclusion-exclusion phenotypic approach is
important, as many of the markers used to identify NK cells
can also be expressed on other cell types (eg, NKT cells also
express NK1.1). The ability to mediate antibody-dependent
cell-mediated cytotoxicity is another important dis-
tinguishing activity mediated by NK cells. As more and more
of the biology of these cells has been gleaned over the years,
it is clear that they are far more complex than originally
thought and they comprise different subsets with a very
unique receptor system that regulates their innate ability to
detect and attack targets. It is the emergence of these subsets
that indicate NK cells exert important functions outside of
cellular cytotoxicity.
NK Cell Biology
The original studies on NK cells and their biology were
performed using inbred mice. Early studies indicated that
these cells were critically dependent on the bone marrow
microenvironment for development and differentiation as
marrow ablation resulted in loss of in vivo function [40].
Indeed, NK cells were at 1 point called “M cells” because of
this dependence on the marrow, which made them distinct
from other hematopoietically derived lymphoid cells (ie, T
and B cells), which could develop by extramedullarly
hematopoiesis [40]. NK cells predominantly circulate in the
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they can also be found in other tissues, particularly after an
inﬂammatory response to infection. Numerous cytokines
play a role in NK cell development and/or function. Initially,
IL2 was used to demonstrate activating and proliferative
effects on NK cells, but it was later found that although this
cytokine was sufﬁcient to induce these responses, it was not
obligatory, as IL2 knockout mice displayed normal NK cell
function [41]. The critical importance of IL15 for NK cell
development and homeostasis was demonstrated by the
absence of NK cells in IL15 and IL15R knockout mice, and by
the inability of these mice to support the survival of adop-
tively transferred mature NK cells [42]. There are multiple
stages in NK cell development that precede exportation into
the circulation and functional maturation. Pivotal on these is
acquisition of MHC-binding receptors. These receptors allow
the NK cell to “see” and respond to virally infected and
transformed cells. Herein also is a signiﬁcant divergence
between mouse and man. Human NK cells express the killer
cell immunoglobulin-like receptor (KIR), which binds to HLA
class I molecules. Mouse NK cells express Ly49 molecules,
which are structurally distinct but functionally similar to
KIRs. Both of these receptors recognize MHC class I mole-
cules and have ITIM (inhibitory) or ITAM (activating)
signaling motifs, which dramatically affect NK cell activity.
Adding to these are other receptor systems (NKG2A and D,
2B4), which also have ITIM and ITAM motifs and affect
function. They are not exclusive and NK cells bear many of
these receptors in differing amounts, which affects overall
net function on NK when it binds to a target. These receptors
can also be modulated depending on the environment [43],
which also affects overall responses. It is the existence of
these different yet similar receptor systems that indicates NK
cells have developed to be tightly controlled. Although they
represent an important arm of the innate immune response,
protection from auto-reactive responses mediated by NK
cells is pivotal. There are also other cell types and cytokines
that regulate NK cell function and development. Regulatory T
cells have been demonstrated to directly inhibit NK cell
activity in vitro and suppress their ability to reject allogeneic
HSCs in vivo [44]. Transforming growth factorebeta is a
cytokine that also suppresses NK cell function, although it
can also be produced by activated NK cells [45]. It is the
understanding of agents that activate NK cells as well as
pathways that inhibit their function that has drawn much
interest with regard to clinical applications in cancer.
NK Cell Modeling
To understand NK cell biology and potential clinical
applications, it is imperative to have an appropriate model.
As the initial studies characterizing NK cells were done using
inbred mice, it is perhaps not surprising that the majority of
subsequent studies and assessment of potential clinical
applications have also been performed in mice. However, as
more has been gleaned from human studies either by in vitro
assessment or by observing effects after clinical trials, it is
very clear that there are signiﬁcant differences between the
species that need to be taken into consideration before
extrapolating mouse data to humans.
First and foremost, there are signiﬁcant genetic species
differences illustrated by the different receptor systems
(ie, KIR in humans and Ly49 in mice), absence of CD56 on
mouse NK cells and the presence of CD56 subsets (eg,
CD56hi) in the human lymph node, whereas NK cells are
lacking in mouse lymph nodes unless stimulated. Thepresence of these CD56hi NK cell subsets within the human
lymph node indicate that NK cells likely play a role in other
critical functions, such as immune homeostasis and immune
regulation. CD56lo NK cells in peripheral blood are highly
lytic, whereas the CD56hi subset secretes cytokines but is
poorly lytic [46]. There are also differences in the ability to
culture NK cells long term, as mouse NK cells invariably die
after several weeks in culture despite optimal cytokines,
whereas human NK cells are able to be cultured for much
greater periods of time and even cloned [40,47]. Another
large variable is the simple fact that inbred mice are housed
under speciﬁc pathogen-free conditions and this can mark-
edly affect NK cell function. Regardless, the similarities
between the species still far outweigh the differences and
simply need to be kept under consideration.
Classically, NK cells have been demonstrated to mediate
direct antitumor and antiviral immunity. First, they have
shown to be capable of mediating direct killing of the
aforementioned cell types. NK cells kill by perforin/gran-
zyme, which results in direct lysis of the cell and can be
assessed by short-term assays. NK cells also kill by fas ligand
and TNF-related apoptosis-inducing ligand (TRAIL) [48], and
this can be observed using longer term in vitro assays. Finally,
NK cells can also secrete effector cytokines, such as
interferon-gamma and TNF [49]. All of these pathways likely
work in concert in vivo and contribute to the net function of
the NK cell on a pathogen. Recently, it has been elegantly
demonstrated that NK cells also exert potent immunoregu-
latory functions on adaptive immune responses during viral
infection. It was observed that NK cells could directly inhibit T
cellemediated responses andmemory to viral infections [50].
This study indicated that the NK cell was capable of directly
killing the activated T cells, resulting in lesser pathology
during the viral infection. Interestingly, it was also recently
demonstrated that NK cells and Tcells could directly compete
with each other with regard to their effector functions [51]
and numbers, indicating that a complex pattern exists
affecting the overall immune response. This in part could be
due to direct (ie, killing of activated T cells via NKG2D ligand
recognition) and indirect (ie, competition for cytokines, such
as IL15) mechanisms. Additionally, NK cells have been
demonstrated to modulate immune responses by both pro-
moting and killing dendritic cells [52]. It is likely the overall
or net immunoregulatory function of NK cells is contingent
on the location and extent of the inﬂammatory response.
NK cells classically have been demonstrated to mediate
resistance to viral infections, although certain viruses (eg,
CMV) have developed means to avoid NK cell attack by
pirating MHC-like domains and, thus, directly inhibiting NK
responses [53]. In mice, murine CMV resistance has also
been shown to be affected by NK cells expressing the
Ly49H-activating receptor (in C57BL/6 mice), which has an
ITAM and leads to the expansion and activation of this
subset in response to infection [54]. Additionally, as NK cells
are the ﬁrst lymphoid cell to repopulate after HSCT, studies
in mice have shown even greater roles for them after HSCT
and subsequent infection. Furthermore, it has been
reported that as opposed to what is classically thought to be
an innate cell type, the expanded Ly49Hþ NK cells exhibit
“memory” responses upon reinfection, thus blurring the
lines between NK and T cells [55]. The role of other NK
subsets in these responses has not been clariﬁed but it is
likely that subsets with different ITIM receptors play dif-
ferential roles, based on the observation that these subsets
undergo different developmental responses due to
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subsets bearing different Ly49 receptors in mice are capable
of binding self MHC to varying degrees. Those capable of
strongly binding self MHC have been reported to exhibit an
increased ability to produce interferon-gamma in response
to stimulation in vitro versus those NK cells bearing Ly49 or
NKG2A receptors with ITIM that bind weakly [56]. The
physiological role of licensing during viral infections is still
unclear, but as with T cell subsets (ie, Th1, Th2, Th17, reg-
ulatory T cells), differential effects will likely be observed.
The observation that the different subsets in mice had
different biologic effects was ﬁrst reported using allogeneic
HSCT and looking at engraftment as a readout [40]. It was
observed that the MHC-binding capability of the different
Ly49 members could affect whether resistance occurred.
When a host NK cell came across an allogeneic HSC not
bearing “self” MHC to turn off the NK cell, the HSC would
then be attacked, resulting in graft rejection. It was in this
manner that the different Ly-49 subsets could be shown to
play a speciﬁc role in HSC rejection contingent on the MHC
haplotype of the recipient. It was also demonstrated that NK
cells could mediate resistance to any allogeneic hema-
topoietically derived cell, including lymphocytes, as well as
preferentially target transformed cells of hematopoietic
origin. In mouse HSCT models, it was also demonstrated
that NK cells of donor origin could suppress GVHD and
promote graft-versus tumor effects in part through their
production of TGFebeta [57]. This was then extended with
preclinical and clinical studies indicating that NK cell sub-
sets could indeed inﬂuence outcome after allogeneic HSCT
based on Ly49 (mouse) or KIR (human) expression and
haplotype.
CONCLUSIONS
Since its description in neonates in the early 20th century
as the cytomegalic inclusion disease, characterized by an
often fatal systemic infection associatedwith the detection of
large cells in the urine, CMV has remained something of an
enigma. During recent decades, advances in diagnostic tests
and treatments have improved our ability to manage CMV
infection in immunocompromised hosts, but the virus still
accounts for signiﬁcant morbidity and mortality. New anti-
viral drugs, and advances in our ability to utilize virus-
speciﬁc T cells to hasten immune reconstitution will likely
provide further patient beneﬁts in coming years. Further
dissection of the roles of both innate and adaptive immunity
will also play a role. It is important to remember that the
current delicate balance that exists between pathogen and
host, which seems so well adapted as to maintain an almost
symbiotic relationship, is relatively easily perturbed with
potentially catastrophic consequences, and that our under-
standing of the full spectrum of risks and beneﬁts of CMV
infection and its interactions with the host immune system
remains far from complete.
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